Table 1
From the following article
Nature Biotechnology 26, 11 - 12 (2008)
doi:10.1038/nbt0108-11
Table 1. Selected research collaborations
| Partner 1 | Partner 2 | $ (millions) | Details |
|---|---|---|---|
BH | |||
| Regeneron Pharmaceuticals (Tarrytown, New York) | Sanofi-Aventis (Paris) | 1,122 | The deal focuses on fully human therapeutic antibodies using Regeneron's VelociSuite of technologies, including VelocImmune. Sanofi-Aventis increased its ownership of Regeneron to about 19% by purchasing 12 million shares at $26 apiece, and will pay $85 million upfront, with another $475 million for research over the next five years. Development costs will be shared, and Regeneron is entitled to receive up to $250 million for milestones on aggregate annual ex-US sales levels, starting at $1 billion. |
| MorphoSys (Munich) | Novartis (Basel) | >1,000 | The companies have an established relationship; this deal makes Novartis MorphoSys's preferred collaborator for HuCAL-based antibody drug discovery. The expanded alliance includes rights for MorphoSys to co-sell codeveloped products in specific territories. Novartis also plans to internalize MorphoSys's Human Combinatorial Antibody Library technology at its research sites. The deal includes $600 million in committed funding over ten years, and milestone payments could push the total to more than $1 billion. |
| Biogen Idec (Cambridge, Massachusetts) | Neurimmune Therapeutics (Zürich) | 380 | The companies agreed on worldwide development and commercialization of novel, fully human antibodies for Alzheimer's disease. Neurimmune will use its reverse translational medicine platform, and Biogen Idec will be responsible for development and commercialization. Neurimmune could receive $380 million in upfront and milestone payments, as well as royalties. |